References
- Vital Statistics, Ministry of Health, Labor Welfare Japan2014 Available from: http://www.mhlw.go.jp/english/new-info/Accessed December 12, 2015
- FukuchiYFernandezLKuoHPEfficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trialRespirology201116582583521539680
- IshikawaNHattoriNKohnoNKobayashiAHayamizuTJohnsonMAirway inflammation in Japanese COPD patients compared with smoking and nonsmoking controlsInt J Chron Obstruct Pulmon Dis20151018519225670894
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseGlobal Initiative for Chronic Obstructive Lung Disease (GOLD 2016) Available from: http://www.goldcopd.comAccessed January 6, 2016
- Japanese Respiratory SocietyGuidelines for the Diagnosis and Treatment of COPD4th editionJapanese Respiratory Society2013 Available from: https://www.jrs.or.jp/modules/guidelines/index.php?content_id=1Accessed December 12, 2015
- BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
- DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
- MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
- WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- AsaiKMinakataYHirataKQVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE studyEuropean Respiratory Society Annual Congress 2013Barcelona, Spain2013P3392
- HoritaNKanekoTRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in JapanInt J Chron Obstruct Pulmon Dis20151081382225960646
- CalverleyPPauwelsRAJonesPWAndersonJAVestbosJThe severity of airways obstruction as a determinant of treatment response in COPDInt J Chron Obstruct Pulmon Dis20061320921818046858
- VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
- ZhongNWangCZhouXLANTERN InvestigatorsLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
- WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med2014108101498150725135743